Compare Crispr Therapeutics AG (CRSP) vs Honest Company Inc (HNST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs Honest Company Inc — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while Honest Company Inc trades at $5.07 (market cap $533.20M). The key difference: Crispr Therapeutics AG is far larger — about 9.2× Honest Company Inc's market cap, and Honest Company Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Honest Company Inc for 39 Days on average.
| CRSP | HNST | |
|---|---|---|
Market Cap | $4.88B | $533.20M |
Volume | 2,861,747 | 1,990,155 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $5.95 |
52-Week Low | $44.34 | $2.10 |
Typical Hold Time | 77 Days | 39 Days |
Enterprise Value | $3.30B | $436.81M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
HNST trades at $4.97, up 0.81% with a bearish technical outlook despite recent institutional buying. The company shows mixed fundamentals with Q2 2026 earnings beating estimates but negative profit margins and declining revenue guidance for 2026. Analyst consensus is cautious with a $5.30 price target and 30% buy rating distribution.
The stock faces headwinds from negative profitability and competitive pressures, though strategic exits show early turnaround signs. Upside potential exists if margin improvements continue, but investors should weigh execution risks against institutional accumulation trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About Honest Company Inc
The Honest Co Inc is a consumer products company. It offers eco-friendly diapers and a natural line of bath, skincare, home cleaning, and organic nutritional supplement products and other products.
Read more on HNST →
